Read more: http://www.bloglution.com/2013/08/how-to-enable-rss-auto-discovery-in.html#ixzz2ik0NTKwC

Saturday, December 29, 2012

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2012:MarketResearchReports.biz


Global Markets Directs, 'Wet (Neovascular / Exudative) Macular Degeneration Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration. Wet (Neovascular / Exudative) Macular Degeneration Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.
 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

  • A snapshot of the global therapeutic scenario for Wet (Neovascular / Exudative) Macular Degeneration.
  • A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

To Browse All  Reports Kindly visit: http://www.marketresearchreports.biz/


Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
To Buy A Copy Of This Report Kindly visit:  http://www.marketresearchreports.biz/analysis/156164

No comments:

Post a Comment